Aims Left ventricular thrombus (LVT) increases the risk of thrombotic events and mortality.
Vitamin K antagonists (VKAs) used to treat LVT have several known risks, as a result of …

Meta-analysis may increase the risk of random errors. Trial sequential analysis (TSA) has
been developed to adjust for these random errors. We conducted TSA on the efficacy and …

Left ventricular thrombi (LVTs) increase the risk of stroke, systemic embolism, and
subsequent death. Current guidelines recommend vitamin K antagonists (VKAs) as first-line …

Background Since the introduction of direct oral anticoagulants (DOACs) and their
comparison with vitamin K antagonists (VKAs), conflicting results have been reported …

Aim of the Study. To evaluate the utilization of oral antithrombotic agents, non‐vitamin K
antagonist oral anticoagulants (NOACs), vitamin K antagonists (VKAs), or antiplatelet …

Evidence on the treatment for left ventricular (LV) thrombus is limited and mainly derives
from retrospective studies. The aim of R-DISSOLVE was to explore the effectiveness and …

Background: Patients with ventricular thrombus (VT) require anticoagulation therapy and it
remains unknown that whether non-vitamin K antagonist oral anticoagulants (NOACs) or …

Clinical Cardiology Contemporary Review of the Management of Left Ventricular Thrombus
Page 1 © The Author(s) 2023. Published by Radcliffe Group Ltd. www.JAPSCjournal.com …

Background: To describe the characteristics, treatment practices, and clinical outcomes of
patients with ventricular mural thrombus (VMT), with emphasis on the comparison of non …

Abstract Background: Vitamin K antagonists (VKAs) are the recommended first-line
treatment for left ventricular thrombus (LVT); however, direct oral anticoagulants (DOACs) …